| Product Name | IL9 Receptor antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Mouse monoclonal [33423] to IL9RHuman Interleukin 9 (IL9) was first identified based on its proliferative activity on a human myeloid leukemic cell line. Human IL9 stimulates the proliferation of the human megakaryocytic leukemic cell line M07e. Human IL9 supports erythroid colony formation and synergizes with IL4 in the production of IgE and IgG. The interleukin 9 receptor is a member of the hematopoietin receptor superfamily. The cDNAs encoding mouse and human IL9 receptors have been isolated. The deduced mouse and human transmembrane proteins, sharing 53% amino acid sequence identity, contain 468 and 533 amino acid residues, respectively. A number of isoforms of IL9R, including a putative soluble form, have also been identified. The IL9 receptor is expressed in a variety of hematopoietic cells including T cells, neutrophils, mast cells, and macrophages. |
| Immunogen | Recombinant full length protein (Human). |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Clone Number | 33423 |
| Host Species | Mouse |
| Tested Applications | ELISANeutWB |
| ELISA: Use at a concentration of 0.5 - 1.0 μg/ml. The detection limit for soluble human IL9 receptor is approximately 6 ng/well. Neut: Use at a concentration of 2-4 μg/ml. WB: Use at a concentration of 1 - 2 μg/ml. Detects a band of approximately 29 kDa. The detection limit for human IL9 receptor is approximately 25 ng/lane under non reducing and reducing conditions. The Neutralization Dose50 (ND50) for anti-human IL9R is approximately 2-4 μg/ml in the presence of 2 ng/ml of recombinant human IL9 using human MO7e cells. The ND50 is the concentration of antibody required to yield one half maximal inhibition of the cytokine activity on a responsive cell line, when that cytokine is present at a concentration just high enough to elicit a maximum response. The exact concentration of antibody required to neutralize the human cell surface IL9R mediated bioactivity is dependent on the IL-9 concentration, as well as on the number and types of IL9 receptors present on the cell surface (a function of cell type and culture conditions). Optimal dilutions/concentrations should be determined by the end user.: |
|
| Species Reactivity | Human |
| Concentration | 0.5mg/ml |
| Purification | Protein A |
| Gene Synonyms | IL9 R IL9R CD129 |
|---|---|
| Target | IL9-R |
| Cellular Localization | Plasma membrane and Secreted |
| Application Notes | ELISA: Use at a concentration of 0.5 - 1.0 μg/ml. The detection limit for soluble human IL9 receptor is approximately 6 ng/well. Neut: Use at a concentration of 2-4 μg/ml. WB: Use at a concentration of 1 - 2 μg/ml. Detects a band of approximately 29 kDa. The detection limit for human IL9 receptor is approximately 25 ng/lane under non reducing and reducing conditions. The Neutralization Dose50 (ND50) for anti-human IL9R is approximately 2-4 μg/ml in the presence of 2 ng/ml of recombinant human IL9 using human MO7e cells. The ND50 is the concentration of antibody required to yield one half maximal inhibition of the cytokine activity on a responsive cell line, when that cytokine is present at a concentration just high enough to elicit a maximum response. The exact concentration of antibody required to neutralize the human cell surface IL9R mediated bioactivity is dependent on the IL-9 concentration, as well as on the number and types of IL9 receptors present on the cell surface (a function of cell type and culture conditions). Optimal dilutions/concentrations should be determined by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Preservative: NoneConstituents: PBS containing 5% Trehalose. |
